Working… Menu

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04463004
Recruitment Status : Active, not recruiting
First Posted : July 9, 2020
Last Update Posted : February 17, 2021
Kiniksa Pharmaceuticals, Ltd.
Information provided by (Responsible Party):
Virginia Commonwealth University